GW Pharmaceuticals PLC- (NASDAQ:GWPH) – Equities research analysts at Svb Leerink boosted their Q4 2019 earnings per share estimates for shares of GW Pharmaceuticals PLC- in a report issued on Tuesday, November 5th. Svb Leerink analyst M. Goodman now expects that the biopharmaceutical company will post earnings of ($0.06) per share for the quarter, up from their prior estimate of ($1.08). Svb Leerink also issued estimates for GW Pharmaceuticals PLC-‘s FY2020 earnings at $0.00 EPS, FY2021 earnings at $0.65 EPS, FY2022 earnings at $1.20 EPS and FY2023 earnings at $1.85 EPS.

Several other research analysts also recently weighed in on the company. BidaskClub downgraded GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a report on Saturday. Bank of America reiterated a “buy” rating and issued a $218.00 price target on shares of GW Pharmaceuticals PLC- in a report on Wednesday, September 25th. Oppenheimer cut their price target on GW Pharmaceuticals PLC- to $222.00 and set an “outperform” rating for the company in a report on Wednesday. ValuEngine upgraded GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Wednesday, September 4th. Finally, Cowen reissued a “buy” rating and set a $200.00 price objective on shares of GW Pharmaceuticals PLC- in a research note on Friday, July 26th. One analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have given a buy rating to the company. GW Pharmaceuticals PLC- has an average rating of “Buy” and an average price target of $198.00.

Shares of GWPH opened at $109.41 on Friday. The stock’s 50 day moving average is $122.70 and its two-hundred day moving average is $154.23. The company has a current ratio of 8.31, a quick ratio of 7.59 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $4.16 billion, a PE ratio of -10.36 and a beta of 2.28. GW Pharmaceuticals PLC- has a twelve month low of $90.14 and a twelve month high of $196.00.

In other news, insider Douglas B. Snyder sold 3,756 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $13.88, for a total transaction of $52,133.28. Following the completion of the sale, the insider now directly owns 79,164 shares of the company’s stock, valued at approximately $1,098,796.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Douglas B. Snyder sold 5,424 shares of the business’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $13.04, for a total transaction of $70,728.96. Following the sale, the insider now directly owns 73,740 shares of the company’s stock, valued at $961,569.60. The disclosure for this sale can be found here. 3.60% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in GWPH. Kavar Capital Partners LLC purchased a new stake in GW Pharmaceuticals PLC- during the 2nd quarter worth $26,000. Signaturefd LLC boosted its position in GW Pharmaceuticals PLC- by 192.5% during the 3rd quarter. Signaturefd LLC now owns 234 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 154 shares during the period. Prestige Wealth Management Group LLC purchased a new stake in GW Pharmaceuticals PLC- during the 2nd quarter worth $28,000. Pathstone Family Office LLC purchased a new stake in GW Pharmaceuticals PLC- during the 2nd quarter worth $29,000. Finally, Valeo Financial Advisors LLC boosted its position in GW Pharmaceuticals PLC- by 322.6% during the 3rd quarter. Valeo Financial Advisors LLC now owns 262 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 200 shares during the period. 82.89% of the stock is owned by institutional investors.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Recommended Story: Street Name

Earnings History and Estimates for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.